UNSPSC 51384625: Benzydamine hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H23N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2GI407R4Q, chemically known as 3-((1-benzyl-1h-indazol-3-yl)oxy)-n,n-dimethylpropylamine monohydrochloride but more generally known as benzydamine hydrochloride, which bears US NIH Compound Identifier 65464. European Medicines Agency schedules Benzydamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00737MIG.

UNSPSC 51384625 Benzydamine hydrochloride is a Commodity code. State and local governments use it to procure specific pharmaceutical active ingredients and finished pharmaceutical products for public health, emergency response, and community health programs. Recent solicitations under this code show that issuing bodies are purchasing naloxone and drug deactivation systems for emergency medical response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and exploring direct-to-manufacturer prescription fulfillment programs to optimize pharmacy benefit costs. The mix of issuing bodies includes county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). Vendors must comply with federal drug manufacturing standards, supply-chain security regulations, and state procurement requirements including E-Verify, insurance coverage thresholds, and good manufacturing practice certification.

Recent activity spans Florida, Texas, Minnesota, and Oregon through cooperative purchasing mechanisms. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, on a two-year contract with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026, response deadline for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with contract performance beginning July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling future formal procurement activity. Cooperative purchasing vehicles dominate the landscape, allowing vendors to serve multiple jurisdictions through single award mechanisms with administrative fee structures and price-competitiveness weighting.